MetaCap

Amgen (AMGN) vs argenx (ARGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amgen (AMGN) has outperformed argenx (ARGX) over the past year, gaining 29.1% versus a gain of 0.7%. Over five years, ARGX leads with a +235.3% price change compared with +116.6% for AMGN. Amgen is the larger company by market cap ($235.64 billion vs $58.21 billion), about 4.0 times the size.

On valuation, Amgen trades at a lower forward P/E (17.3x vs 27.8x for argenx). Amgen pays a dividend yielding 2.28%, while argenx does not currently pay one.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMGN+29.06%ARGX+0.74%
+45%+7%-31%
Nov 21, 20251 yearNov 20, 2026
AMGN+111.39%ARGX+225.99%
+280%+129%-23%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMGN versus ARGX key metrics
MetricAMGNARGX
Share price$435.64$925.70
Market cap$235.64B$58.21B
1-day change-0.15%-1.73%
YTD return+33.10%+10.08%
1-year return+29.06%+0.74%
5-year return+116.64%+235.28%
P/E ratio (TTM)25.2532.06
Forward P/E17.3427.79
EPS (TTM)$17.25$28.87
Dividend yield2.28%0.00%
Annual dividend$9.94$0.00
Revenue (latest FY)$36.75B—
Revenue growth (YoY)+9.95%—
Net income (latest FY)$7.71B$1.29B
Gross margin67.25%—
Operating margin24.71%—
Net margin20.98%—
52-week high$483.99$1,072.75
52-week low$312.39$661.85
Distance from 52-week high-9.99%-13.71%
Analyst consensusholdbuy
Avg. price target upside-0.88%+24.30%
Average volume2.82M359.65K
Shares outstanding540.91M62.89M
Employees31,5001,863
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Amgen is about 4.0 times larger than argenx by market value ($235.64B vs $58.21B).
  • AMGN has outperformed ARGX by 28.3 percentage points over the past year.
  • argenx trades at a higher earnings multiple (32.1x vs 25.3x trailing P/E).
  • Amgen offers a meaningfully higher dividend yield (2.28% vs 0.00%).

About Amgen

AMGN stock →

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees

About argenx

ARGX stock →

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees

AMGN vs ARGX FAQ

Which is bigger, Amgen or argenx?

Amgen (AMGN) is larger, with a market capitalization of $235.64B compared with $58.21B for argenx (ARGX).

Which stock has performed better over the past year, AMGN or ARGX?

AMGN returned +29.06% over the past 12 months, compared with +0.74% for ARGX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, AMGN or ARGX?

AMGN has the lower trailing P/E at 25.3, versus 32.1 for ARGX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Amgen or argenx?

Amgen pays a dividend yielding 2.28%, while argenx does not currently pay a regular dividend.

Are Amgen and argenx in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons